CSIMarket Company Name, Ticker, Industry, else..
 
Pharmacyte Biotech Inc   (NASDAQ: PMCB)
Other Ticker:  
 
 
Price: $1.2100 $0.07 5.677%
Day's High: $1.2729 Week Perf: -2.32 %
Day's Low: $ 1.15 30 Day Perf: -22.93 %
Volume (M): 3 52 Wk High: $ 2.42
Volume (M$): $ 3 52 Wk Avg: $1.77
Open: $1.15 52 Wk Low: $1.03



 Market Capitalization (Millions $) 8
 Shares Outstanding (Millions) 7
 Employees 5
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 18
 Cash Flow (TTM) (Millions $) -45
 Capital Exp. (TTM) (Millions $) 0

Pharmacyte Biotech Inc
Pharmacyte Biotech Inc. is a biotechnology company that focuses on developing medical treatments for cancer and diabetes. They are known for their innovative technology called Cell-in-a-Box, which involves encapsulating living cells in a protective coating. This technology allows for the targeted delivery of therapeutic cells to specific areas of the body, potentially offering more effective treatment options. Pharmacyte Biotech Inc. is committed to improving the lives of patients by developing novel therapies that have the potential to combat these devastating diseases.


   Company Address: 3960 Howard Hughes Parkway Las Vegas 89169 NV
   Company Phone Number: 595-2850   Stock Exchange / Ticker: NASDAQ PMCB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
APTO   -51%    
ENTX        9.7% 
HLVX        7.14% 
INAB        6.88% 
VIR        6.88% 
VXRT        6.88% 
• View Complete Report
   



Business Update

PharmaCyte Biotech Joins Forces with MyMD Pharmaceuticals with a $7 Million Investment to Revolutionize Inflammatory Disease Therapies

Published Tue, May 21 2024 1:51 PM UTC

PharmaCyte Biotech Invests $7 Million in MyMD Pharmaceuticals to Develop Novel Therapies for Inflammatory DiseasesPharmaCyte Biotech, a renowned biotechnology company specializing in cellular therapies for various diseases, has made a strategic investment of $7 million in MyMD Pharmaceuticals, a clinical-stage biopharmaceutical company focused on addressing age-related disea...
Pharmacyte Biotech Inc

Pharmacyte Biotech Inc Faces Growing Financial Challenges in Fiscal Third Quarter of 2024

The Biotechnology & Pharmaceuticals industry insiders have begun to analyze the third-quarter earnings of 2024. As of now, the industry insiders have observed an operating loss of $-1.868946 million from a particular company, which has not yet disclosed any revenue for the period from November to January 31, 2024. In order to provide some context for the recent performance, it is worth comparing it to the same period in 2023, when the company reported an operating loss of $-1.552983 million.
One of the notable observations from the third quarter of 2024 earnings season, apart from the absence of revenue, is the significant increase in net deficit. The company recorded a net deficit of $-1.401 million, which is considerably higher than the $-0.764 million reported in the corresponding financial reporting period a year ago.
Pharmacyte Biotech Inc

PMCB Sets New Milestone in Biotech & Pharma Industry with Game-Changing Q2 2024 Earnings Report

The Biotechnology & Pharmaceuticals sector has been an important focal point in the recent reporting season, which took place from August to October 31, 2023. Many businesses within this sector have announced their earnings, with some notable mentions. One such company is Pharmacyte Biotech Inc, which disclosed an operating deficit of $-1.40952 million during the most recent fiscal period.
This operating deficit is a significant contrast to the same time-frame a year ago, highlighting a considerable decline in the company's recent performance. It is particularly noteworthy as Pharmacyte Biotech Inc predominantly operates in the expansion period, making this downturn a major takeaway from the current scenario.
Pharmacyte Biotech Inc

Pharmacyte Biotech Inc Records Severe Operating Loss in Q1 2024

Pharmacyte Biotech Inc: Analyzing Changes in Company Performance
The stockholders of Pharmacyte Biotech Inc were taken by surprise during the May to July 31, 2023 reporting cycle, as unforeseen changes occurred within the business. These changes were primarily reflected in the company's operating loss, which amounted to $-2.075326 million during the aforementioned period. For investors, monitoring this operating loss was crucial in assessing the company's performance.
To better understand the recent fiscal period results, it is important to analyze the preceding quarter. The operating loss in the first quarter of 2023 was $-1.680608 million, indicating a slight improvement compared to the subsequent period. It is worth noting that businesses often experience fluctuating performance, especially when trying to stimulate lucrative revenue streams. The May to July 31, 2023 period was one such instance where shortfalls extended to $-3.183 million.
Pharmacyte Biotech Inc

Pharmacyte Biotech Inc. Springs Unexpected Positive Turnaround in Q2 2023 Report, Recording Operating Loss of -$0.903283 Million



Pharmacyte Biotech Inc, a leading biotechnology and pharmaceutical company, recently reported its financial performance for the period from February to April 30, 2023. The company's operating loss of $-0.903283 million during this period demonstrates a significant improvement compared to the same period a year before, reflecting positive growth for shareholders.
Investors had not anticipated the modifications in revenue during the reporting season, making the decrease in operating loss a pleasant surprise. Compared to a corresponding loss of $-1.507701 million a year earlier, this improved figure has instilled optimism among market participants.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com